ECONOMIC BURDEN ON DIABETES AND CARDIOVASCULAR DISEASE: REAL WORLD DATA AND EMPIRICAL ANALYSIS IN ALGERIA

Tebaibia A¹⁻², A. Mammeri ¹⁻², F. Hamrour ¹⁻², O. Hocine¹⁻², M. Ammi¹⁻², N. Slimani¹⁻², S. Zekri¹⁻², Aissaoui A³, Hachelaf Z³ Internal Medicine Department, EPH El Biar (Ex. Birtraria), Algiers, Algeria1, Algiers University 1, Algeria2 Sanofi Algeria3

Poster # **EE475 ISPOR 2023** Nov 12–15, 2023 Copenhagen Denmark

BACKGROUND

- other In Algeria, many as in developing countries, the number of people with type 2 diabetes İS reaching **14.4%**₂ increasing Of prevalence, this is mainly due to urbanization, an aging population, a sedentary lifestyle and an unbalanced diet₁.
- Cardiovascular disease is a leading cause of death in Algeria, a direct consequence of a growing prevalence various cardiovascular the Of metabolic risk factors₃.
- All these increases diabetes IN prevalence and its complications has led to significant economic burden for healthcare system

POSTER HIGHLIGHTS

Internal

Figure 2: Patient characteristic



RESULTS (continued)

comorbidity or complication related to diabetes which was hypertension and 56% for cardiovascular disease groupe which was diabetes. Total direct cost was 1.4millions euros (almost 600K € for cardiovascular disease and 812 K € for diabetes).

average The cost of care is significantly higher for diabetic a patient versus cardiology patient, a gap of 67%.

This gap widens further when it comes to the average cost of a hospitalized patient, since between a diabetes and cardiovascular disease patient, the difference is estimated at $\approx 146\%$. It is estimated that there is a difference of 72% between the average cost of a diabetes patient vs cardiovascular disease patient when seen in visits. a patient admitted to the For emergency room, there is no difference in average cost between a diabetes and cardiovascular disease patient. Average medical resources consumed per diabetes patient is 1 058,40 € (560,50 € for drug costs, 147,49€, for Tests and diagnosis costs, 325,19 € physician costs and 25,22 € for nurses costs) and for cardiovascular disease patients 584,99 € (146,02 € for drug costs, 152,82€, for Tests and diagnosis costs, 263,10 € physician costs and 23,05 € for nurses costs)

 In our Knowledge, no specific study has evaluated this economic burden in Algeria.

OBJECTIVE

To assess direct cost of diabetes cardiovascular diseases and hospital from management perspective

To compare these costs based on real world data.

METHODS

- This was an observational, monocentric, retrospective study conducted during 2 years (2019 & 2020) from patients medical records.
- Study population:
- Number of patients included are 2300
- Patient inclusion criteria: Patient

								• / •
0	10	20	30	40	50	60	70	
■ Car	diovasc	ular dise	ease	Diabete	es			

Visits Emergency Hospitalization Cardiovascular disease Diabetes

Figure 3: Complications description



DISCUSSION

This study provides the first and one of the most detailed descriptions of inpatient resource utilization from hospital perspective, patient cohort was large which allowed to obtain a statistically significant results.

- diagnosed in diabetes and cardiovascular disease at service level during study period.
- Availability of the patient's medical record containing medical data and resources used by the patient during his or her disease management
- Participating Center:

Study was set up in internal medicine department in EPH* Birtraria Algiers, Algeria.





*Other costs : All costs not involved in t direct management of the disease : ,: administrative, financial, IT costs **Direct costs : physician costs, nurse costs, drug costs & Tests and diagnosis costs

Figure 5 : Costs per patient



- Diabetes care appears to be costly in cardiovascular comparison to this costs, is mainly diseases explained by higher treatment cost of this pathology, this study suggests further that this cost item is the highest overall hospital expenditure,
- Other resources spent during the study period of 2 years for both patient sub remains groups equivalent
- there is no local study that As assessed this type of cost, it is not possible to perform comparison

The limits of this study :

Only hospital perspective disease management and costs was considered, other costs were note included.

This study has captured the patients characteristic and cost elements for 2300 patients at the internal medicine department, which represents 46% of total patients, repartition per therapeutic area is 54% for cardiology and 37% for diabetology, remaining 6 % were suffering from other pathologies managed in the internal medicine service. Average age of patient groups is 64 years for cardiovascular disease and 60 years for diabetes. 85% of diabetes patients had at least one

costs	147,49 EUR
Drug costs	560,50 EUR
Nurse costs	25,22 EUR
Physician costs	325,19 EUR
Total costs	1 058,40 EUR



Detailed cost of complications and other disease costs were not assessed.

CONCLUSIONS

Diabetes and cardiovascular disease healthcare utilization are significantly high, the direct costs generated by these diseases in Algeria represent a real economic and societal burden for patients and health authorities.

These results will help raise awareness and stimulate further scientific research investment for these disease and management, resource optimization, and improved quality of life for patients.

FUNDING : This study was sponsored by Sanofi.

1-Brondex A. et all , 2012/ 2-WHO stepwise, 2017/3-Cardiometabolic risk in Algeria: past and present, A. Mammer, A. Tebaibia, October 2019